Integra LifeSciences Holdings Corporation
IARTHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Integra LifeSciences Holdings Corporation (IART) is listed under Medical Devices. The company carries a $926.3M market cap, placing it firmly in the small-cap category. It operates through Codman Specialty Surgical and Tissue Technologies segments.
Market Cap
$926.3M
Beta
1.21
P/E (TTM)
70.06
P/E (Fwd)
4.99
EPS (TTM)
$0.17
EPS (Fwd)
$2.39
ROE
1.2%
ROA
3.1%
Cash
$311.9M
Total Debt
$2.00B
Free CF
$116.0M
52W Change
-25.2%
Annual Financials
Cash vs Debt
Where IART stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IART finished 10.33% below its 150-day moving average ($15.00) and 4.54% below its 200-day moving average ($14.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IART overbought or oversold?
At the October 20, 2026 close, IART's RSI(14) was 29.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $311.9M in cash, though total debt stands at $2.00B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $116.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 1.2% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.1% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $1.56B (2022) to $1.64B (2025).
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Integra LifeSciences Holdings Corporation's trajectory.